|
Solvent |
mg/mL |
mM |
comments |
| Solubility |
| DMSO |
40.0 |
114.20 |
|
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
350.26
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Desai RI, Terry P, Katz JL. A comparison of the locomotor stimulant effects of D1-like receptor agonists in mice. Pharmacol Biochem Behav. 2005 Aug;81(4):843-8. doi: 10.1016/j.pbb.2005.06.006. PMID: 16000217.
2: Desai RI, Terry P, Katz JL. Comparison of the discriminative-stimulus effects of SKF 38393 with those of other dopamine receptor agonists. Behav Pharmacol. 2003 May;14(3):223-8. doi: 10.1097/00008877-200305000-00006. PMID: 12799524.
3: Spealman RD, Bergman J, Rosenzweig-Lipson S. Differential modulation of behavioral effects of cocaine by low- and high-efficacy D1 agonists. Psychopharmacology (Berl). 1997 Oct;133(3):283-92. doi: 10.1007/s002130050403. PMID: 9361335.
4: Kleven MS, Koek W. Differential effects of direct and indirect dopamine agonists on eye blink rate in cynomolgus monkeys. J Pharmacol Exp Ther. 1996 Dec;279(3):1211-9. PMID: 8968343.
5: DaSilva JN, Wilson AA, Nobrega JN, Jiwa D, Houle S. Synthesis and autoradiographic localization of the dopamine D-1 agonists [11C]SKF 75670 and [11C]SKF 82957 as potential PET radioligands. Appl Radiat Isot. 1996 Mar;47(3):279-84. doi: 10.1016/0969-8043(95)00306-1. PMID: 8935965.
6: Bergman J, Spealman RD, Madras BK, Rosenzweig-Lipson S. Agonist efficacy and the behavioral effects of dopamine D1 receptor ligands: drug interaction studies in squirrel monkeys. J Pharmacol Exp Ther. 1996 Mar;276(3):942-50. PMID: 8786574.
7: DaSilva JN, Wilson AA, Valente CM, Hussey D, Wilson D, Houle S. In vivo binding of [11C]SKF 75670 and [11C]SKF 82957 in rat brain: two dopamine D-1 receptor agonist ligands. Life Sci. 1996;58(19):1661-70. doi: 10.1016/0024-3205(96)00141-5. PMID: 8632703.
8: Tomiyama K, Koshikawa N, Funada K, Oka K, Kobayashi M. In vivo microdialysis evidence for transient dopamine release by benzazepines in rat striatum. J Neurochem. 1995 Dec;65(6):2790-5. doi: 10.1046/j.1471-4159.1995.65062790.x. PMID: 7595579.
9: Gnanalingham KK, Hunter AJ, Jenner P, Marsden CD. Stimulation of adenylate cyclase activity by benzazepine D-1 dopamine agonists with varying efficacies in the 6-hydroxydopamine lesioned rat--relationship to circling behaviour. Biochem Pharmacol. 1995 May 11;49(9):1185-93. doi: 10.1016/0006-2952(95)00035-x. PMID: 7763300.
10: Bergman J, Rosenzweig-Lipson S, Spealman RD. Differential effects of dopamine D1 and D2 receptor agonists on schedule-controlled behavior of squirrel monkeys. J Pharmacol Exp Ther. 1995 Apr;273(1):40-8. PMID: 7714795.
11: Gnanalingham KK, Hunter AJ, Jenner P, Marsden CD. The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease. Psychopharmacology (Berl). 1995 Feb;117(3):287-97. doi: 10.1007/BF02246103. PMID: 7770604.
12: Gnanalingham KK, Erol DD, Hunter AJ, Smith LA, Jenner P, Marsden CD. Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset. Psychopharmacology (Berl). 1995 Feb;117(3):275-86. doi: 10.1007/BF02246102. PMID: 7770603.
13: Terry P, Witkin JM, Katz JL. Pharmacological characterization of the novel discriminative stimulus effects of a low dose of cocaine. J Pharmacol Exp Ther. 1994 Sep;270(3):1041-8. PMID: 7932151.
14: Rosenzweig-Lipson S, Hesterberg P, Bergman J. Observational studies of dopamine D1 and D2 agonists in squirrel monkeys. Psychopharmacology (Berl). 1994 Sep;116(1):9-18. doi: 10.1007/BF02244865. PMID: 7862937.
15: Rosenzweig-Lipson S, Bergman J. Catalepsy-associated behavior induced by dopamine D1 receptor antagonists and partial dopamine D1 receptor agonists in squirrel monkeys. Eur J Pharmacol. 1994 Aug 1;260(2-3):237-41. doi: 10.1016/0014-2999(94)90343-3. PMID: 7988649.
16: Rosenzweig-Lipson S, Bergman J. Dopamine D1 receptor involvement in the discriminative-stimulus effects of SKF 81297 in squirrel monkeys. J Pharmacol Exp Ther. 1993 Nov;267(2):765-75. PMID: 7902432.
17: Alam AM, Starr MS. D1 agonists suppress zero Mg(2+)-induced epileptiform activity in the rat cingulate cortex slice. Neuroreport. 1993 Oct 25;5(1):78-80. doi: 10.1097/00001756-199310000-00021. PMID: 7506591.
18: Johanson CE, Barrett JE. The discriminative stimulus effects of cocaine in pigeons. J Pharmacol Exp Ther. 1993 Oct;267(1):1-8. PMID: 8229735.
19: Izenwasser S, Katz JL. Differential efficacies of dopamine D1 receptor agonists for stimulating adenylyl cyclase in squirrel monkey and rat. Eur J Pharmacol. 1993 Jun 15;246(1):39-44. doi: 10.1016/0922-4106(93)90007-v. PMID: 8102607.
20: Starr MS, Starr BS. Seizure promotion by D1 agonists does not correlate with other dopaminergic properties. J Neural Transm Park Dis Dement Sect. 1993;6(1):27-34. doi: 10.1007/BF02252620. PMID: 8105796.
